Nakagawa K, Kurobe M, Ozono K, Konno K, Fujishima T, Takayama H, Okano T
Department of Hygienic Sciences, Kobe Pharmaceutical University, Kobe, Japan.
Biochem Pharmacol. 2000 Mar 15;59(6):691-702. doi: 10.1016/s0006-2952(99)00357-3.
We evaluated the biological activity of two sets of ring A stereoisomers of 2-methyl-1alpha,25-dihydroxyvitamin D(3) (2-methyl-1alpha,25(OH)(2)D(3)) and 2-methyl-20-epi-1alpha, 25-dihydroxyvitamin D(3) (2-methyl-20-epi-1alpha,25(OH)(2)D(3)) in terms of the following: transactivation of a rat 25-hydroxyvitamin D(3)-24-hydroxylase gene promoter including two vitamin D response elements (VDREs) and a human osteocalcin gene promoter including a VDRE in transfected human osteosarcoma (MG-63) cells; a vitamin D receptor (VDR)-mediated response using a VDR-GAL4 one-hybrid luciferase reporter system and a retinoid X receptor alpha (RXRalpha)-mediated response using an expressed VDR/RXRalpha-GAL4 modified two-hybrid luciferase reporter system in transfected human epitheloid carcinoma, cervix (HeLa) cells; and modulation of cell surface CD11b antigen expression in human leukemia (HL-60) cells. All the diastereomers of both analogues exhibited unique biological activity profiles depending upon the configurations of the C-1 and C-3 hydroxyl groups, the C-2 methyl group in ring A, and the C-20 methyl group in the side chain. Of the eight possible diastereomers of the 2-methyl analogues, 2alpha-methyl-1alpha,25(OH)(2)D(3) was the most potent and exhibited comparable or even greater biological potency than 1alpha,25(OH)(2)D(3). Of the eight possible diastereomers of the 2-methyl-20-epi analogues, 2alpha-methyl-20-epi-1alpha,25(OH)(2)D(3) was the most potent and exhibited 100- to 200-fold higher transcriptional potencies than 1alpha,25(OH)(2)D(3) and exceptionally high cell regulatory activities. 2beta-methyl-20-epi-1alpha,25(OH)(2)D(3) was nearly as potent as its 2-epimer, 2alpha-methyl-20-epi-1alpha,25(OH)(2)D(3), whereas its 20-epimer, 2beta-methyl-1alpha,25(OH)(2)D(3), was almost completely biologically inactive. In these respects, it can be postulated that the double modification of 2-methyl substitution and 20-epimerization to 1alpha,25(OH)(2)D(3) induces remarkable changes in a VDR/RXRalpha/VDRE-mediated signaling response and greatly enhances biological activity. The other striking finding was that 2beta-methyl-20-epi-3-epi-1beta,25(OH)(2)D(3) is transcriptionally more active than 1alpha,25(OH)(2)D(3) despite lacking the 1alpha-hydroxyl group, which was believed to be essential for expressing VDR-mediated gene transcription. Since the C-20 natural counterpart, 2beta-methyl-3-epi-1beta,25(OH)(2)D(3), was almost completely biologically inactive, 20-epimerization is probably responsible for activation of gene expression. Although earlier extensive structure-activity studies of vitamin D analogues showed stereochemistry at the C-1, C-3, and C-20 of 1alpha,25(OH)(2)D(3) to be the key structural motif for vitamin D action, our results clearly demonstrated that stereochemistry at the C-2 is also an important structural motif for vitamin D action and imply that 2-methyl substitution possibly induces conformational changes in ring A depending upon the combinations of configurations of the C-1 and C-3 hydroxyl groups with C-20 stereochemistry. Consequently, several of these analogues exhibit exceptionally high or unexpected biological activities at the molecular and cellular levels. These results suggest that 2-methyl substitution together with alterations of stereochemistry in both ring A and the side chain of 1alpha, 25(OH)(2)D(3) will provide useful analogues for structure-activity studies and development of therapeutic agents with unique biological activity profiles.
我们从以下几个方面评估了两组2-甲基-1α,25-二羟基维生素D₃(2-methyl-1α,25(OH)₂D₃)和2-甲基-20-表-1α,25-二羟基维生素D₃(2-methyl-20-epi-1α,25(OH)₂D₃)的A环立体异构体的生物活性:在转染的人骨肉瘤(MG-63)细胞中,对包含两个维生素D反应元件(VDREs)的大鼠25-羟基维生素D₃-24-羟化酶基因启动子和包含一个VDRE的人骨钙素基因启动子的反式激活;在转染的人上皮样癌、宫颈(HeLa)细胞中,使用VDR-GAL4单杂交荧光素酶报告系统的维生素D受体(VDR)介导的反应以及使用表达的VDR/RXRα-GAL4修饰双杂交荧光素酶报告系统的视黄酸X受体α(RXRα)介导的反应;以及在人白血病(HL-60)细胞中对细胞表面CD11b抗原表达的调节。两种类似物的所有非对映异构体均表现出独特的生物活性谱,这取决于C-1和C-3羟基的构型、A环中的C-2甲基以及侧链中的C-20甲基。在2-甲基类似物的八种可能的非对映异构体中,2α-甲基-1α,25(OH)₂D₃最具活性,并且表现出与1α,25(OH)₂D₃相当甚至更高的生物活性。在2-甲基-20-表类似物的八种可能的非对映异构体中,2α-甲基-20-表-1α,25(OH)₂D₃最具活性,并且表现出比1α,25(OH)₂D₃高100至200倍的转录活性以及异常高的细胞调节活性。2β-甲基-20-表-1α,25(OH)₂D₃与其2-表异构体2α-甲基-20-表-1α,25(OH)₂D₃的活性几乎相同,而其20-表异构体2β-甲基-1α,25(OH)₂D₃几乎完全没有生物活性。在这些方面,可以推测2-甲基取代和20-表异构化对1α,25(OH)₂D₃的双重修饰会诱导VDR/RXRα/VDRE介导的信号反应发生显著变化,并大大增强生物活性。另一个显著发现是,尽管缺乏被认为是表达VDR介导的基因转录所必需的1α-羟基,但2β-甲基-20-表-3-表-1β,25(OH)₂D₃的转录活性比1α,25(OH)₂D₃更高。由于C-20天然对应物2β-甲基-3-表-1β,25(OH)₂D₃几乎完全没有生物活性,因此20-表异构化可能是基因表达激活的原因。尽管早期对维生素D类似物进行的广泛构效关系研究表明,1α,25(OH)₂D₃的C-1、C-3和C-20处的立体化学是维生素D作用的关键结构基序,但我们的结果清楚地表明,C-2处的立体化学也是维生素D作用的重要结构基序,这意味着2-甲基取代可能会根据C-1和C-3羟基构型与C-20立体化学的组合诱导A环的构象变化。因此,这些类似物中的几种在分子和细胞水平上表现出异常高或意想不到的生物活性。这些结果表明,2-甲基取代以及1α,25(OH)₂D₃的A环和侧链立体化学的改变将为构效关系研究和开发具有独特生物活性谱的治疗药物提供有用的类似物。